Glycogen synthase kinase-3 in patients with bipolar I disorder: results from a prospective study

Imagem de Miniatura
Arquivos
art_JACOBY_Glycogen_synthase_kinase3_in_patients_with_bipolar_I_2016.PDF (351.33 KB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
JACOBY, Anne S.
MUNKHOLM, Klaus
VINBERG, Maj
KESSING, Lars V.
Citação
BIPOLAR DISORDERS, v.18, n.4, p.334-341, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
ObjectivesThe enzyme glycogen synthase kinase-3 (GSK3) is involved in the mechanisms of action of lithium and may play a role in relation to affective states in bipolar disorder. The objectives of the present study were to compare the activity of GSK-3 (measured as levels of phosphorylated GSK-3 [p-GSK-3]) between patients with bipolar disorder in the euthymic state and healthy control subjects, and to investigate whether GSK-3 activity varies with affective states in patients with bipolar I disorder. MethodsIn a prospective 6-12-month follow-up study, we investigated state-specific, intraindividual alterations in the activity of GSK-3 in 60 patients with bipolar I disorder with an acute severe manic index episode and in subsequent euthymic, depressive and manic states and compared this with repeated measurements in healthy control subjects. Data were analyzed using linear mixed-effects models. ResultsFrom baseline to the end of follow-up, blood samples were drawn from the 60 patients during 181 affective states, comprising 60 manic, 11 mixed, 23 depressive, and 87 states of euthymia. A total of 69 blood samples were drawn from 35 healthy control subjects, with two samples from the same subject taken three months apart. In mixed-model analysis, p-GSK-3 was decreased in the euthymic state of subjects with bipolar disorder compared with healthy control subjects (b=0.63, 95% confidence interval [CI]: 0.42-0.96, P=.03). In addition, p-GSK-3 varied with affective states, being increased in depressive (b=1.68, 95% CI: 1.08-2.62, P=.02) and mixed (b=2.07, 95% CI: 1.12-3.84, P=.02) states but not in mania compared with euthymia. ConclusionsThe activity of GSK-3 is altered in euthymic bipolar disorder compared with healthy control subjects and varies with affective states.
Palavras-chave
bipolar disorder, glycogen synthase kinase-3, GSK3, mania
URI
https://observatorio.fm.usp.br/handle/OPI/16297
Referências
  1. Andrezza A, 2010, BIPOLAR DISORDER CLI, P228
  2. Castri P, 2007, EUR J NEUROSCI, V26, P2469, DOI 10.1111/j.1460-9568.2007.05869.x
  3. desSousa RT, 2015, J PSYCHIATR RES, V62, P78
  4. Diniz BS, 2011, WORLD J BIOL PSYCHIA, V12, P216, DOI 10.3109/15622975.2010.551408
  5. Du J, 2010, P NATL ACAD SCI USA, V107, P11573, DOI 10.1073/pnas.0913138107
  6. EMBI N, 1980, EUR J BIOCHEM, V107, P519
  7. Fountoulakis KN, 2008, INT J NEUROPSYCHOPH, V11, P269, DOI 10.1017/S1461145707007821
  8. Gladkevich A, 2004, PROG NEURO-PSYCHOPH, V28, P559, DOI 10.1016/j.pnpbo.2004.01.009
  9. Goldstein BI, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0425-9
  10. Hamilton M., 1967, BR J SOC CLIN PSYCHO, V6, P278, DOI 10.1111/J.2044-8260.1967.TB00530.X
  11. Joaquim HPG, 2012, J PSYCHIATR RES, V46, P1053, DOI 10.1016/j.jpsychires.2012.04.020
  12. Jope RS, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00016
  13. Kapczinski Flavio, 2008, Expert Rev Neurother, V8, P1101, DOI 10.1586/14737175.8.7.1101
  14. Kapczinski F, 2008, NEUROSCI BIOBEHAV R, V32, P675, DOI 10.1016/j.neubiorev.2007.10.005
  15. Kessing LV, 2012, J PSYCHOPHARMACOL, V26, P644, DOI 10.1177/0269881111414091
  16. Kessing LV, 2011, BRIT J PSYCHIAT, V199, P57, DOI 10.1192/bjp.bp.110.084822
  17. Kessing LV, 2004, BRIT J PSYCHIAT, V185, P372, DOI 10.1192/bjp.185.5.372
  18. Kessing LV., 2015, DAN MED J, V62, P1
  19. Ladeira RB, 2013, REV BRAS PSIQUIATR, V35, P274, DOI 10.1590/1516-4446-2012-0921
  20. Li XH, 2010, BIPOLAR DISORD, V12, P741, DOI 10.1111/j.1399-5618.2010.00866.x
  21. Li XH, 2007, BIOL PSYCHIAT, V61, P216, DOI 10.1016/j.biopsych.2006.02.027
  22. Lohoff FW, 2010, BIPOLAR DISORDER CLI, P110
  23. Munkholm K, 2015, BIPOLAR DISORD, V17, P257, DOI 10.1111/bdi.12245
  24. Munkholm K, 2015, BRAIN BEHAV IMMUN, V43, P205, DOI 10.1016/j.bbi.2014.09.021
  25. Munkholm K, 2014, PSYCHONEUROENDOCRINO, V47, P199, DOI 10.1016/j.psyneuen.2014.05.011
  26. Munkholm K, 2016, NEUROPSYCHOBIOLOGY, V73, P108, DOI 10.1159/000444489
  27. Munkholm K, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyu101
  28. Pandey GN, 2010, J PSYCHIATR RES, V44, P143, DOI 10.1016/j.jpsychires.2009.07.009
  29. Peineau S, 2008, BRIT J PHARMACOL, V153, pS428, DOI 10.1038/bjp.2008.2
  30. Polter A, 2010, NEUROPSYCHOPHARMACOL, V35, P1761, DOI 10.1038/npp.2010.43
  31. Severus Emanuel, 2014, Int J Bipolar Disord, V2, P15, DOI 10.1186/s40345-014-0015-8
  32. Sullivan PF, 2006, AM J MED GENET B, V141B, P261, DOI 10.1002/ajmg.b.30272
  33. Wang HZ, 2011, CYTOKINE, V53, P130, DOI 10.1016/j.cyto.2010.10.009
  34. WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589
  35. YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/27